Condition: Dyspareunia · Sponsor: Teva Pharmaceuticals USA
Randomized, double-blind, placebo-controlled, parallel-designed, multiple-site, bioequivalence study with clinical endpoints.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Site 10112 | Birmingham, Alabama, United States | — |
| Site 10146 | Chandler, Arizona, United States | — |
| Site 10103 | Sacramento, California, United States | — |
| Site 10124 | Sacramento, California, United States | — |
| Site 10135 | San Diego, California, United States | — |
| Site 10136 | Milford, Connecticut, United States | — |
| Site 10130 | Edgewater, Florida, United States | — |
| Site 10123 | Hialeah, Florida, United States | — |
| Site 10139 | Lake Worth, Florida, United States | — |
| Site 10115 | Leesburg, Florida, United States | — |
| Site 10138 | Maitland, Florida, United States | — |
| Site 10107 | Miami Lakes, Florida, United States | — |
+ 36 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05617820